secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017860
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q1 net loss $24.8M, cash $129.4M; key trial readouts on track for late 2023
--------------------------------------------------------------------------------

- Net loss of $24.8M in Q1 2023 vs $18.5M in Q1 2022; R&D expenses rose to $12.6M (up $2.4M YoY).
- Cash and equivalents $129.4M at Mar 31, 2023; expected to fund operations into H1 2025.
- Phase 2b MM-120 for GAD and Phase 2a for ADHD both on track for topline results in late 2023.
- Appointed Mark R. Sullivan as Chief Legal Officer in April 2023.
- Plan to initiate Phase 1 trial of MM-402 for ASD in 2023; pre-clinical data at ASCP May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/0000950170-23-017860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023017860/mnmd-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer